New Targets in Inflammation : Inhibitors of Cox-2 or Adhesion Molecules. This item is unavailable.New Targets in Inflammation : Inhibitors of Cox-2 or Adhesion Molecules

This volume contains the proceedings of the William Harvey Research Conference held in New Orleans on the 15th and 16th of April 1996. It reviews the general pathophysiological significance of the isoforms of cyclooxygenase and the likely value of selective COX-2 inhibitors in the treatment of rheumatoid conditions. The volume also covers the possible use of antibodies against cytokines and cell adhesion receptors in the treatment of inflammatory conditions.

Jack Botting is Consultant at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK. Sir John Vane is the Director General at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK.
Sir John Vane shared the Nobel Prize in Physiology or Medicine in 1982 for his discoveries of the mechanism of action of aspirin and of prostacyclin, as well as his work on other prostanoids.